Skip to main
LQDA

LQDA Stock Forecast & Price Target

LQDA Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 67%
Buy 22%
Hold 0%
Sell 11%
Strong Sell 0%

Bulls say

Liquidia Corp has demonstrated impressive growth potential, with adjusted sales estimates for YUTREPIA now projected at peak sales of $1.7 billion to $2 billion, reflecting stronger than anticipated uptake among patients with pulmonary hypertension. The successful launch of YUTREPIA has enabled Liquidia to achieve operating profitability within the first full quarter of its commercial release, supported by compelling data on patient outcomes such as a significant increase in the six-minute walk distance. Additionally, the favorable tolerability profile of the L606 device, coupled with insights on the strategic use of the drug sotatercept, reinforces Liquidia's competitive edge in addressing unmet medical needs within the pulmonary hypertension market.

Bears say

Liquidia Corp faces considerable legal risks that threaten the exclusivity of its primary revenue source, YUTREPIA, particularly due to ongoing lawsuits regarding patent rights. The outcome of these legal challenges, especially concerning the '327 patent with a potential expiration in 2042, poses significant downside risk to the company’s financial stability and its future growth prospects. Additionally, even a favorable resolution for the long-term operations of YUTREPIA may not prevent short-term disruptions in sales, contributing to the stock's current valuation discount relative to its growth potential.

LQDA has been analyzed by 9 analysts, with a consensus rating of Buy. 67% of analysts recommend a Strong Buy, 22% recommend Buy, 0% suggest Holding, 11% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Liquidia Technologies Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Liquidia Technologies Inc (LQDA) Forecast

Analysts have given LQDA a Buy based on their latest research and market trends.

According to 9 analysts, LQDA has a Buy consensus rating as of Feb 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $39, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $39, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Liquidia Technologies Inc (LQDA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.